利沃多巴-协同CBT干预改善了通过调节BDNF/PI3K/AKT通路来调节焦虑障碍的帕金森病

相关实验视频

Updated: May 28, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Niu Ji^1,2, Shujin Lu^1,3, Bingchao Xu²

¹Nanjing Medical University, No. 101, Longmian Avenue, Jiangning District, Nanjing, Jiangsu Province, 211166, China.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

|February 12, 2025

概括

认知行为治疗 (CBT) 有效地治疗帕金森病 (PD) 患者的焦虑. 结合CBT和药物治疗可以改善抑郁症,焦虑症和生活质量,减少跌倒并提高患者满意度.

科学领域:

神经科学是一个神经科学.
精神病学是一个精神病学.
药理学药理学是指药理学的学科.

背景情况:

焦虑障碍是帕金森病 (PD) 患者常见和致残的疾病.
它显著影响患者的生活质量和预后.

研究的目的:

分析PD患者焦虑的危险因素.
评估认知行为疗法 (CBT) 对患有焦虑障碍 (PDAD) 的PD的有效性.

主要方法:

评估了211名PD和139名PDAD患者,分析了风险因素.
在PDAD患者中,比较CBT与临床管理组 (CMO).
利用小鼠PD模型研究焦虑机制和L-dopa对BDNF/PI3K/Akt通路的影响.

主要成果:

患有PDAD的患者表现出更高的焦虑评分;PSQI,ESS,HAMD,SCOPA-AUT,UPDRS-III和Hoehn-Yahr被确定为危险因素.
与CMO相比,CBT显著改善了心理状态,认知功能和生活质量.
在小鼠中,L-dopa减轻了焦虑,增加了BDNF,p-PI3K和p-Akt水平,L-dopa和CBT的联合显示了增强的效果.

结论:

认知行为疗法 (CBT) 是对帕金森病焦虑的有效治疗方法.
将药物与CBT结合使用可以改善PDAD患者的抑郁,焦虑和生活质量.
通过CBT干预,导致跌倒较少,患者满意度更高.

关键词:

焦虑症是一种焦虑障碍.这就是为什么BDNF是BDNF.认知行为疗法是一种认知行为疗法.在PI3K/Akt.帕金森病的疾病.

更多相关视频

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...